Gastric cancer, a leading cause of cancer-related deaths, is a heterogeneous disease. We
aim to establish clinically relevant molecular subtypes that would encompass this …

Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a
subset of patients with metastatic gastric cancer (mGC). With the goal of identifying …

… Collection and assembly of data: Se Hoon Park, Min Eui Hong, Kyoung-Mee Kim, Min
Gew Choi, Jun Ho Lee, Jae Moon Bae, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho …

This study highlights response heterogeneity within MSI-H gastric cancer treated with
pembrolizumab monotherapy and underscores the potential for extended baseline and early on-…

Although RAF monomer inhibitors (type I.5, BRAF(V600)) are clinically approved for the
treatment of BRAF V600 -mutant melanoma, they are ineffective in non-BRAF V600 mutant cells …

Prospective clinical sequencing revealed that baseline heterogeneity between tumor samples
from different patients affected response to biomarker-selected therapies. VIKTORY is the …

Using paired pretreatment and on-treatment samples during standard first-line chemotherapy,
we identify chemotherapy-induced NK-cell infiltration, macrophage repolarization, and …

Background ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers.
Pioneer cases of metastatic colorectal cancer (mCRC) patients bearing rearrangements who …

Accurate detection of genomic alterations using high-throughput sequencing is an essential
component of precision cancer medicine. We characterize the variant allele fractions (VAFs) …

… Seung Tae Kim … Seung Tae Kim … Fairclough, Hyuk Lee, Kyoung-Mee Kim, Seung Tae
Kim, Jinchul Kim, Danielle Gavino, Manuel Benavides, Nir Peled, Timmy Nguyen, Mike Cusnir, …